Unfortunately, information on breast cancer subtype (HR+/HER2−; HER2+; triple negative) was unavailable for too many patients from the 2010–2013 time period (74% missing values) to allow any conclusions about different effects of breast cancer screening on different breast cancer subtypes (Figure S6 in the supplement). Here, ERBB2 is linked to breast carcinoma.